PROGRAM Information

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with irritable bowel syndrome (IBS).

Educational Objectives

After completing this program, participants should be better able to:

Apply evidence-based diagnostic criteria to evaluate patients presenting with symptoms suggestive of IBS/CIC

Identify patients with alarm symptoms who require further diagnostic investigation

Incorporate evidence-based treatment plans for patients with IBS-C/CIC effectively into practice

Incorporate evidence-based treatment plans for patients with IBS-D effectively into practice

Provided by

For more information, email us at, or call 1-877-782-4532.



Brooks D.
Cash, MD

William D.
Chey, MD

Anthony J.
Lembo, MD

Moshiree, MD

Pimentel, MD


Judge's Opening Remarks and Preliminary Instructions:

• Summary of Standard of Care and Recent Treatment Advances
in IBS and CIC

• Description of Cases, Roles, and Responsibilities

Trial in Session with Expert Arguments

Opening Statement / Plaintiff's Case / Defendant's Case


IBS Is a Symptom-Based Diagnosis


Dietary Changes Are Effective in Managing IBS Symptoms


IBS/CIC Should Be Treated with Nonprescription Medications

Closing Statements and Jury Vote

Verdict Summary, Judge's Statement, and Panel Q&A


Brooks D. Cash, MD, FACG
Professor of Internal Medicine
Chief, Gastroenterology Division
University of South Alabama Health System
Mobile, Alabama

Back to Agenda

Brooks D. Cash, MD, is a professor of internal medicine at the University of South Alabama (USA), in Mobile, Alabama, where he has held a faculty position since 2013 and currently serves as Chief of the Gastroenterology Division and director of the Motility and Physiology Laboratory at the USA Digestive Health Center. Dr. Cash served in the United States Navy for 24 years, retiring in 2013 as the Deputy Commander for Medicine at Walter Reed National Military Medical Center at the rank of captain. He continues to serve as a professor of medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.

Dr. Cash received his undergraduate degree with honors in Business Administration (Finance) from the University of Texas at Austin. He earned his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his internship, residency, and gastroenterology fellowship at the National Naval Medical Center in Bethesda.

Dr. Cash is a Diplomat of the American Board of Gastroenterology, a Fellow of the American College of Physicians, American College of Gastroenterology, American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. He has served as chair for numerous professional society committees as well as course director for national and regional ACG postgraduate meetings. Dr. Cash has served on the Rome Committee for Functional Gastrointestinal Disorders and has authored multiple articles and book chapters on a wide variety of gastrointestinal topics, including IBS and chronic constipation, colorectal cancer screening, CT colonography, acid peptic disorders, Barrett's esophagus, medical education techniques, and evidence-based medicine. He serves as an associate editor for the American Journal of Gastroenterology and is an editorial board member and reviewer for multiple internal medicine and gastroenterology medical journals. He is the 2016 recipient of the William Carey award from the American College of Gastroenterology.


Consultant:  Allergan, AstraZeneca, IMHealthScience, Prometheus, Sebela, Salix Pharmaceuticals, Shionogi, Torax.

Speaker's Bureau:  Allergan, AstraZeneca, IMHealthScience, Prometheus, Salix Pharmaceuticals, Shionogi, Torax.

Advisory Board Membership:  Allergan, AstraZeneca, Salix Pharmaceuticals, Synergy.

Editorial Board Involvement:  American Journal of Gastroenterology

William D. Chey, MD
Director – GI Physiology Lab
Director – Nutrition & Lifestyle Program
Michigan Medicine
Ann Arbor, Michigan

Back to Agenda

Dr. Chey received his BA degree from the University of Pennsylvania and his medical degree and training in internal medicine at the Emory University School of Medicine. He completed a fellowship in gastroenterology at the University of Michigan in Ann Arbor. Following completion of his fellowship, Dr. Chey remained at the University of Michigan where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology, director of the GI Physiology Laboratory, co-director of the Michigan Bowel Control Program, and director of the GI Nutrition and Behavioral Wellness Program. In 2011, Dr. Chey was named H. Marvin Pollard Institute Scholar at the University of Michigan. He was awarded a joint appointment in the Department of Nutrition Sciences in 2015.

His research interests focus on the diagnosis and treatment of functional bowel disorders, acid-related disorders, and Helicobacter pylori infection. Dr. Chey has been funded by federal and private sources. He is a medical innovator who holds 4 patents. He co-founded "My Total Health", a company that develops novel health-information technology solutions for persons with GI problems.

Dr. Chey has authored more than 350 manuscripts, reviews, chapters, and books. He is co-editor-in-chief of the American Journal of Gastroenterology (2010–2016), founding co-editor-in-chief of Clinical and Translational Gastroenterology (2011–2014), and he serves on the editorial boards of several other medical journals.

Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology (ACG) and joined the Board of Directors of the ACG Institute in 2014. He is a member of the Board of Directors of the Rome Foundation and is on the editorial board for the Rome IV criteria. He is an advisory board member of the International Foundation of Functional GI Disorders.

He has been elected to "Best Doctors" since 2001 and to “America’s Top Doctors” since 2009. In 2015, Dr. Chey was named one of the “190 Gastroenterologists to Know” by Becker’s ASC Review. In 2014, Dr. Chey was inducted into the Clinical Excellence Society of the Department of Medicine, received the Dean’s Outstanding Clinician Award, and was inducted into the League of Research Excellence at the University of Michigan. In 2015, he was also inducted into the League of Clinical Excellence at the University of Michigan and received the Distinguished Clinician Award from the American Gastroenterological Association.


Grant/Research Support:  Ardelyx, Ironwood Pharmaceuticals, Inc., Nestle Health Science, QOL Medical, Vibrant.

Consultant/Honorarium Recipient:  Allergan, Biomerica, Ironwood Pharmaceuticals, Inc., Nestle Health Science Prometheus Laboratories, Inc., Ritter Pharmaceuticals, Inc., Salix Pharmaceuticals, Synergy Pharmaceuticals.

Anthony J. Lembo, MD
Associate Professor of Medicine
Harvard Medical School
Director, GI Motility Laboratory
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Back to Agenda

Dr. Anthony J. Lembo, also known as Tony, M.D., C-IBS serves as a Director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center's (BIDMC) Division of Gastroenterology in Boston, MA. Dr. Lembo serves as an Associate Professor of Medicine at Harvard Medical School. Dr. Lembo has been a Member of Scientific Advisory Board at Biomerica Inc. since July 25, 2016. Dr. Lembo has been a Member of Clinical Advisory Board at Synthetic Biologics Inc. since October 15, 2014. He serves as a Member of the Advisory Board at Echelon Ventures for LumeRx. Following his fellowship he joined the faculty at UCLA Medical Center where he was Co-Director of the Functional Bowel Disorders and GI Motility Center. In 1997, he joined the faculty at BIDMC. He is an accomplished expert in afflictions of the gastrointestinal tract. He divides his time between clinical medicine and research at Beth Israel Deaconess Hospital in Boston. He has authored several original research articles and served on editorial and review boards for several publications, including The American Journal of Gastroenterology, Gastroenterology, Digestive Diseases and Sciences, American Journal of Family Practice and Current Opinion in Gastroenterology. He subsequently completed his Internal Medicine Internship/Residency as well as Gastroenterology Fellowship at UCLA Medical Center in Los Angeles, CA. Dr. Lembo is a graduate of Amherst College, has earned an M.D. from Tufts Medical School.


Advisory Board Member:  Alkermes, Allergan, Ironwood Pharmaceuticals, Inc., Prometheus Laboratories, Inc., Salix Pharmaceuticals, Shire, Takeda, Valeant

Baha Moshiree, MD, MS-CI
Professor of Medicine
Director of Motility
Division of Gastroenterology
Carolinas HealthCare System
Charlotte, North Carolina

Back to Agenda

Baha Moshiree MD, MS-CI will be appointed Professor of Medicine and Director of Motility, in the Division of Gastroenterology at the Carolinas HealthCare System in Charlotte, North Carolina. She has previously completed subspecialty training in gastroenterology at the University of Florida and received a master’s degree in clinical investigation with a focus in functional and motility disorders during fellowship training on a National Institutes of Health (NIH) T32 grant. Dr. Moshiree has previously implemented and built the only comprehensive motility program in South Florida and Miami and is now planning to do the same in Charlotte, NC now starting in November with specific expertise in the diagnosis and management of patients with chronic gastrointestinal illnesses such as complex esophageal disorders, gastroparesis, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), and constipation. The main focus of her research has been the multidimensional pathophysiology of IBS with complex interactions between the sensitizing effects of inflammation, central nervous system disinhibition, gut immunity, and genetic influences. Her publications have examined pain processing mechanisms and brain-gut interactions in patients with IBS. Her research continues to focus on the discovery of biomarkers for the diagnosis of IBS and on new treatments for gastroparesis and small bowel overgrowth. One of her clinical trials will soon be completed in September comparing a Low FODMAP diet to mindfulness based eating behavior in patients with IBS. Dr. Moshiree has presented her research at several national meetings and has received the Presidential Poster Award at the American College of Gastroenterology Meeting and the Poster of Distinction at Digestive Diseases Week; she has also received a Young Investigator Award from the American Motility Society.

In addition to her clinical and research interests, Dr. Moshiree has a strong commitment to education and has received several education awards, including the Outstanding Teaching Award while at University of Florida; Excellence in Mentoring (2011), which is given yearly to only one member from the Department of Medicine at the University of Florida; Excellence in Research awards; and the American Medical Association’s Women Physicians Section (WPS) Inspiration Physician Award (2014). She is on the American Gastroenterology Association’s Institute Council (2014–2016), has served as chair for abstract reviews for national GI meetings, and has co-directed the Florida Gastroenterology Society meeting.


Advisory Board:  Allergan, Synergy Pharmaceuticals, Ironwood, Prometheus Laboratories

Consultant:  Prometheus Laboratories, QOL Medical

Grant recipient:  QOL Medical, Prometheus Laboratories, Medtronics

Mark Pimentel, M.D., FRCP(C)
Executive Director, Medically Associated Science and
Technology (MAST) Program
Professor of Medicine, Geffen School of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Back to Agenda

Mark Pimentel, M.D., is Professor of Medicine, Geffen School of Medicine and Associate Professor at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree, and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease. His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel has been invited to present his work at meetings, grand rounds, and advisory boards in the United States and Internationally. He is diplomate of the American Board of Internal Medicine (Gastroenterology) and a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Pimentel is also a member of several medical associations including the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society.

A few of Dr. Pimentel's most significant accomplishments include:

  1. 1. The discovery of rifaximin as a treatment for irritable bowel syndrome (IBS)
  2. 2. He developed the first blood test for IBS on the basis of IBS being derived
    from acute gastroenteritis
  3. 3. Described the association between IBS and bacterial overgrowth which forms the basis
    for microbiome therapies in this condition
  4. 4. Uncovered the methanogen (M. smithii) as an agent for causing constipation in humans.
  5. 5. Discovered the use of lovastatin as a microbiome treatment for constipation on
    the basis of inhibiting methane production by methanogens


Grants/Research Support:  Valeant

Consultant/Advisory Board Membership/Honorarium Recipient:  Commonwealth Laboratories, LLC, Naia Pharmaceuticals, Synthetic Biologics, Inc., Valeant

Speaker's Bureau:  Valeant

Stockholder:  Naia Pharmaceuticals, Synthetic Biologics, Inc.

Editorial Board Involvement:  American Journal of Gastroenterology

Other Financial Material Support:  Cedars-Sinai has licensing agreements with 4 companies above

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.